Financial Reporting And Growth OutlookAnalyst flags adjustments to free cash flow definitions and working‑capital treatment, together with softer EBITDA growth expectations, as factors that complicate valuation and have driven rating pressure.
Financing Cost And Leverage StrategyAnalyst cautions that reliance on hybrid securities, which carry higher interest costs than traditional debt, raises annual financing expense and reduces the attractiveness of the company's leverage plan.
Transaction Timing RiskAnalyst warns that absence of a disclosed timeline for any health‑business transaction creates uncertainty about when monetization proceeds and strategic benefits will be realized.